HyperImage Project Advances Research on Hybrid PET/MR Scanner Technology
|
By MedImaging International staff writers Posted on 19 Nov 2009 |
An imaging project has achieved a major milestone in its plan to create a new medical imaging technique called hybrid PET/MR. This new technique is based on the simultaneous acquisition of time-of-flight positron emission tomography (PET) and magnetic resonance (MR) images.
The leader of the European Union-funded HYPERImage research project is Philips Healthcare (Best, The Netherlands). The project involves eight partners from six European countries and has a total budget of around EUR 7 million. The ultimate goals of the project are to advance the accuracy of diagnostic imaging in cardiology and oncology and open up new fields in therapy planning, guidance, and response monitoring.
A hybrid PET/MR scanner could simultaneously deliver the anatomic and functional information achievable using state-of-the-art MR scanners (e.g., soft tissue contrast and physiologic processes in blood vessels) and the molecular imaging data provided by PET. As a result, it would combine the best of both worlds, which could ultimately help to pinpoint and characterize disease sites within the body more accurately than is currently possible.
For a hybrid scanner that offers simultaneous PET and MR image acquisition, two basic problems need to be solved: the development of MR-compatible PET detectors and a method of accounting for PET attenuation (the scattering of high-energy gamma rays generated by the PET tracers by parts of the human body).
The milestone that the HYPERImage team has reached is the development of a functional gamma-ray detector that meets the performance requirements of the latest time-of-flight PET scanners. The new gamma-ray detectors have been designed to be compatible with the strong static and dynamic magnetic fields that would be present in a combined PET/MR scanner. Furthermore, the team has achieved major progress with respect to MRI-based static and dynamic PET attenuation correction. Details of these results were presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference, October 25-31, 2--9, in Orlando, FL, USA.
"Understanding the molecular mechanisms associated with cardiovascular disease and cancer, and the development of technologies focused on the early detection of these disease processes are the two main challenges of biomedical research,” said Prof. Dr. Valentin Fuster, director of the National Center for Cardiovascular Research in Madrid, Spain (one of Europe's leading research centers in cardiology) and the Cardiovascular Institute at the Mount Sinai Medical Center in New York, NY, USA. "I am convinced that the realization of a PET/MR technology platform will significantly help to improve the precision and the moment at which disease is diagnosed, two critical parameters for the successful treatment of many diseases.”
"The HYPERImage team's combined expertise in semiconductor physics, signal processing, and medical scanner design, together with its expert clinical knowledge, have moved the project an important step forward in the development of a new imaging tool that is intended to help clinicians diagnose and treat some of the world's most prevalent killer diseases, such as breast cancer,” said Henk van Houten, senior vice president of Philips Research and head of Philips' healthcare research program. "I am proud to say that proof-of-concept of an MR-compatible PET detector took the team less than 1.5 years to achieve. It clearly demonstrates that good collaborations lead to very fast progress.”
The HYPERImage consortium comprises three universities (King's College London, UK; Universität Heidelberg, Germany; and Universiteit Ghent-Institute for Broadband Technology, Belgium), three research foundations (Fundación Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Fondazione Bruno Kessler, Tento, Italy; and The Netherlands Cancer Institute, Amsterdam, The Netherlands), a university medical center (Uniklinikum Hamburg-Eppendorf, Germany) and the industrial partner (Philips, The Netherlands and Germany).
EU funding for the HYPERImage project, which is being provided as part of the EU's 7th Framework Program, amounts to around EUR 5 million. The consortium partners will provide an additional EUR 2.3 million. The project started in 2008 and will run for three years. Philips' leadership of the consortium is based on its
experience in designing and developing medical scanners.
Related Links:
Philips Healthcare
The leader of the European Union-funded HYPERImage research project is Philips Healthcare (Best, The Netherlands). The project involves eight partners from six European countries and has a total budget of around EUR 7 million. The ultimate goals of the project are to advance the accuracy of diagnostic imaging in cardiology and oncology and open up new fields in therapy planning, guidance, and response monitoring.
A hybrid PET/MR scanner could simultaneously deliver the anatomic and functional information achievable using state-of-the-art MR scanners (e.g., soft tissue contrast and physiologic processes in blood vessels) and the molecular imaging data provided by PET. As a result, it would combine the best of both worlds, which could ultimately help to pinpoint and characterize disease sites within the body more accurately than is currently possible.
For a hybrid scanner that offers simultaneous PET and MR image acquisition, two basic problems need to be solved: the development of MR-compatible PET detectors and a method of accounting for PET attenuation (the scattering of high-energy gamma rays generated by the PET tracers by parts of the human body).
The milestone that the HYPERImage team has reached is the development of a functional gamma-ray detector that meets the performance requirements of the latest time-of-flight PET scanners. The new gamma-ray detectors have been designed to be compatible with the strong static and dynamic magnetic fields that would be present in a combined PET/MR scanner. Furthermore, the team has achieved major progress with respect to MRI-based static and dynamic PET attenuation correction. Details of these results were presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference, October 25-31, 2--9, in Orlando, FL, USA.
"Understanding the molecular mechanisms associated with cardiovascular disease and cancer, and the development of technologies focused on the early detection of these disease processes are the two main challenges of biomedical research,” said Prof. Dr. Valentin Fuster, director of the National Center for Cardiovascular Research in Madrid, Spain (one of Europe's leading research centers in cardiology) and the Cardiovascular Institute at the Mount Sinai Medical Center in New York, NY, USA. "I am convinced that the realization of a PET/MR technology platform will significantly help to improve the precision and the moment at which disease is diagnosed, two critical parameters for the successful treatment of many diseases.”
"The HYPERImage team's combined expertise in semiconductor physics, signal processing, and medical scanner design, together with its expert clinical knowledge, have moved the project an important step forward in the development of a new imaging tool that is intended to help clinicians diagnose and treat some of the world's most prevalent killer diseases, such as breast cancer,” said Henk van Houten, senior vice president of Philips Research and head of Philips' healthcare research program. "I am proud to say that proof-of-concept of an MR-compatible PET detector took the team less than 1.5 years to achieve. It clearly demonstrates that good collaborations lead to very fast progress.”
The HYPERImage consortium comprises three universities (King's College London, UK; Universität Heidelberg, Germany; and Universiteit Ghent-Institute for Broadband Technology, Belgium), three research foundations (Fundación Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Fondazione Bruno Kessler, Tento, Italy; and The Netherlands Cancer Institute, Amsterdam, The Netherlands), a university medical center (Uniklinikum Hamburg-Eppendorf, Germany) and the industrial partner (Philips, The Netherlands and Germany).
EU funding for the HYPERImage project, which is being provided as part of the EU's 7th Framework Program, amounts to around EUR 5 million. The consortium partners will provide an additional EUR 2.3 million. The project started in 2008 and will run for three years. Philips' leadership of the consortium is based on its
experience in designing and developing medical scanners.
Related Links:
Philips Healthcare
Latest Nuclear Medicine News
- Targeted PET Platform Guides Osteosarcoma Resection and Margin Verification
- Portable PET System Enables Real-Time Bedside Guidance for Biopsies and Ablations
- AI Model Predicts Radiation Dose Before Prostate Cancer Therapy
- Vault-Free Radiosurgery Platform Expands Access to Cranial Tumor Care
- MR-Guided Cardiac Mapping System Enables Radiation-Free Procedures
- New Imaging Tool Sheds Light on Tumor Fat Metabolism
- PET Tracer Enables Noninvasive Measurement of Beta Cell Mass
- Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies
- Cancer “Flashlight” Shows Who Can Benefit from Targeted Treatments
- PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack
- Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers
- New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer
- PET Tracer Enables Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers
- New Camera Sees Inside Human Body for Enhanced Scanning and Diagnosis
- Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections
- New Imaging Approach Could Reduce Need for Biopsies to Monitor Prostate Cancer
Channels
Radiography
view channel
Rapid X-Ray Test Quantifies Pulmonary Regurgitation After Tetralogy of Fallot Repair
Tetralogy of Fallot is the most common cyanotic congenital heart defect and can leave patients with pulmonary valve regurgitation, a backward flow of blood into the right ventricle after repair.... Read more
AI Tool Flags Osteoporosis Risk from Routine Chest X-Rays
Osteoporosis is a progressive loss of bone density that is often silent until a fracture occurs. Current screening frameworks concentrate on older women and select high-risk groups. Many men, younger adults,... Read moreMRI
view channel
AI Approach Could Shorten Advanced Brain MRI Scans by Up to 90%
Long acquisition times for advanced brain magnetic resonance imaging (MRI) can limit access, extend waiting lists, and disrupt clinical workflows. Reducing data requirements without sacrificing image fidelity... Read more
Cardiac MRI Measure Improves Risk Prediction in Tricuspid Regurgitation
Tricuspid regurgitation, in which blood flows back from the right ventricle into the right atrium, can lead to progressive right-sided heart failure. Clinicians need reliable ways to gauge severity and... Read moreUltrasound
view channelAI Robotic Ultrasound System Automates Echocardiography and Improves Consistency
Echocardiography, an ultrasound examination of the heart, is central to diagnosing and managing cardiovascular disease. Many services struggle with limited availability of skilled sonographers, variable... Read more
Whole Cross-Section Ultrasound System Enables Operator-Independent Imaging
Conventional ultrasound is central to bedside imaging but is limited by a narrow field of view and operator variability. Comprehensive cross-sectional assessment typically requires computed tomography... Read moreGeneral/Advanced Imaging
view channelNew SPECT/CT Method Differentiates Inflammation from Fibrosis in Interstitial Lung Disease
Interstitial lung disease (ILD) encompasses more than 200 disorders that inflame or scar the lung interstitium and can lead to progressive respiratory failure. Determining whether active inflammation is... Read more
Whole-Body PET/CT Tracks Metabolic Changes After Bariatric Surgery
Obesity surgery improves weight and comorbidity profiles, yet clinicians lack tools to monitor organ-level metabolic recovery after the procedure. A clear view of systemic changes could refine follow-up... Read moreImaging IT
view channel
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read moreIndustry News
view channel
GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare is highlighting Intelligent Radiation Therapy (iRT), MIM Software innovations, and BK Medical surgical... Read more




 Guided Devices.jpg)


